News & Updates
Showing Pharmacy articles
Showing
Show Multimedia Only

Dose reduction does not limit efficacy of trastuzumab deruxtecan in MBC
01 Oct 2025
byStephen Padilla
Reducing the dose of trastuzumab deruxtecan (T-DXd) does not have any significant effect on real-world (rw) progression-free survival (PFS) or treatment-related toxicities among patients with metastatic breast cancer (MBC), as shown in a Singapore study.








